• Title/Summary/Keyword: Adjuvant treatment

Search Result 746, Processing Time 0.026 seconds

Lack of Prognostic Impact of Adjuvant Radiation on Oncologic Outcomes in Elderly Women with Breast Cancer

  • Omidvari, Shapour;Talei, Abdolrasoul;Tahmasebi, Sedigheh;Moaddabshoar, Leila;Dayani, Maliheh;Mosalaei, Ahmad;Ahmadloo, Niloofar;Ansari, Mansour;Mohammadianpanah, Mohammad
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.16 no.17
    • /
    • pp.7813-7818
    • /
    • 2015
  • Background: Radiotherapy plays an important role as adjuvant treatment in locally advanced breast cancer and in those patients who have undergone breast-conserving surgery. This study aimed to investigate the prognostic impact of adjuvant radiation on oncologic outcomes in elderly women with breast cancer. Materials and Methods: In this retrospective study, we reviewed and analyzed the characteristics, treatment outcome and survival of elderly women (aged ${\geq}60years$) with breast cancer who were treated and followed-up between 1993 and 2014. The median follow up for the surviving patients was 38 (range 3-207) months. Results: One hundred and seventy-eight patients with a median age of 74 (range 60-95) years were enrolled in the study. Of the total, 60 patients received postoperative adjuvant radiation (radiation group) and the remaining 118 did not (control group). Patients in the radiation group were significantly younger than those in the control group (P value=0.004). In addition, patients in radiation group had higher node stage (P value<0.001) and disease stage (P=0.003) and tended to have higher tumor grade (P=0.031) and received more frequent (P value<0.001) adjuvant and neoadjuvant chemotherapy compared to those in the control group. There was no statistically significant difference between two groups regarding the local control, disease-free survival and overall survival rates. Conclusions: In this study, we did not find a prognostic impact for adjuvant radiation on oncologic outcomes in elderly women with breast cancer.

Is conservative treatment (enucleation using modified Carnoy's solution) of odontogenic keratocyst in the maxilla good prognosis?

  • Woo Young Jeon;Jung Ho Park;Jeong-Kui Ku;Jin-A Baek;Seung-O Ko
    • Journal of the Korean Association of Oral and Maxillofacial Surgeons
    • /
    • v.49 no.5
    • /
    • pp.287-291
    • /
    • 2023
  • Odontogenic keratocysts (OKCs) located in the maxillae have rarely been reported in the literature. Standard treatment modalities for OKC range from marsupialization to marginal resection. However, most of the studies on OKC treatment have been related to mandibular OKCs. The anatomical structure and loose bone density of the maxillae and the empty space of the maxillary sinus could allow rapid growth of a lesion and the ability to tolerate tumor occupancy in the entire maxilla within a short period of time. Therefore, OKCs of the maxillae require more aggressive surgery, suchas resection. As an alternative, this report introduces a modified Carnoy's solution, a strong acid, as an adjuvant chemotherapy after cyst enucleation. This report describes the clinical outcomes of enucleation using a modified Carnoy's solution in patients with large OKCs on the posterior maxillae. In three cases, application of a modified Carnoy's solution had few side effects or morbidity. Each patient was followed for four to six years, and none showed any signs of recurrence. In conclusion, adjuvant treatment with a modified Carnoy's solution can be considered a treatment option capable of reducing the recurrence rate of OKC in the maxillae.

The reasonable timing of the adjuvant radiotherapy in the treatment of uterine carcinosarcoma according to the surgical intent: suggestion based on progression patterns

  • Yu, Jeong Il;Choi, Doo Ho;Huh, Seung Jae;Park, Won;Oh, Dongryul;Bae, Duk Soo
    • Radiation Oncology Journal
    • /
    • v.31 no.2
    • /
    • pp.72-80
    • /
    • 2013
  • Purpose: We designed this study to identify and suggest the reasonable timing of adjuvant radiotherapy in the treatment of uterine carcinosarcoma according to the surgical intent and patterns of progression. Materials and Methods: We retrospectively analyzed a total of 50 carcinosarcoma patients diagnosed between 1995 and 2010. Among these 50 patients, 32 underwent curative surgery and 13 underwent maximal tumor debulking surgery. The remaining five patients underwent biopsy only. Twenty-six patients received chemotherapy, and 15 patients received adjuvant radiotherapy. Results: The median follow-up period was 17.3 months. Curative resection (p < 0.001) and stage (p < 0.001) were statistically significant factors affecting survival. During follow-up, 30 patients showed progression. Among these, eight patients (16.0%) had loco-regional progression only. The patients who had received adjuvant radiotherapy did not show loco-regional progression, and radiotherapy was a significant negative risk factor for loco-regional progression (p = 0.01). The time to loco-regional progression was much earlier for non-curative than curative resection (range, 0.7 to 7.6 months vs. 7.5 to 39.0 months). Conclusion: Adjuvant radiotherapy in the treatment of carcinosarcoma might be related to a low loco-regional progression rate. Radiotherapy should be considered in non-curatively resected patients as soon as possible.

Adjuvant Trastuzumab for 6 Months is Effective in Patients with HER2-positive Stage II or III Breast Cancer

  • Tai, Cheng-Jeng;Pan, Chin-Kwun;Chen, Ching-Shyang;Hung, Chin-Sheng;Wu, Chih-Hsiung;Chiou, Hung-Yi
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.14 no.3
    • /
    • pp.1981-1984
    • /
    • 2013
  • Objective: The optimal duration of adjuvant trastuzumab treatment in patients with HER2-positive breast cancer is not known. The aim of this study was to evaluate the efficacy of 6 months of adjuvant trastuzumab treatment in patients with stage II or III HER2-positive breast cancer. Methods: The records of patients with HER2-positive stage II or III breast cancer who were admitted to the Breast Center of Taipei Medical University Hospital and Yuan's General Hospital between 2000 and 2008 were reviewed. All patients received adjuvant trastuzumab at an initial dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg/week for 22 weeks in combination with chemotherapy. Results: A total of 51 patients were included with a mean age of 46.9 years. Approximately 55% of the patients had stage III disease. The mean follow-up time from initiation of treatment was 45.2 months (range, 0.9 to 85 months). During follow-up, 46 patients (90.2%) did not experience tumor recurrence. The mean estimated disease free survival was 80.2 months. The estimated 1-, 2-, 5-, and 7-year survival rates were 97.9%, 93.1%, 93.1%, and 93.1%, respectively. The most common adverse effects were gastrointestinal symptoms (21.6%), chills (17.6%), dizziness (9.8%), and bone pain (7.8%). No cardiac or hematologic adverse events occurred. Conclusion: Adjuvant therapy with trastuzumab for 6 months resulted in a clinical benefit in patients with HER2-positive breast cancer.

The antinociceptive and anti-inflammatory effect of water-soluble fraction of bee venom on rheumatoid arthritis in rats

  • Lee, Jang-Hern;Kwon, Young-Bae;Lee, Jae-Dong;Kang, Sung-Keel;Lee, Hye-Jung
    • Journal of Pharmacopuncture
    • /
    • v.4 no.1
    • /
    • pp.65-84
    • /
    • 2001
  • We recently demonstrated that bee venom (BV) injection into acupoint (i.e. Zusanli) produced more potent anti-inflammatory and antinociciptive effect in Freunds adjuvant induced rheumatoid arthritis (RA) model as compared with that of non-acupoint injection(i.e back). However, the precise components underlying BV-induced antinociceptive and/or anti-inflammatory effects have not been fully understood. Therefore, we further investigated the anti-arthritic effect of BV after extracting the whole BV according to solubility (water soluble: BVA, ethylacetate soluble: BVE). Subcutaneous BVA treatment (0.9 mg/kg/day) into Zusanli acupoint was found to dramatically inhibit paw edema and radiological change (i.e. new bone proliferation and soft tissue swelling) caused by Freunds adjuvant injection. In addition, the increase of serum interleukin-6 by RA induction was normalized by the BVA treatment as similar with that of non-arthritic animals. On the other hand, BVA therapy significantly reduced arthritis induced nociceptive behaviors (i.e., nociceptive score for mechanical hyperalgesia and thermal hyperalgesia). Furthermore, BVA treatment significantly suppressed adjuvant induced Fos expression in the lumbar spinal cord at 3 weeks post-adjuvant injection. However, BVE treatment (0.05 mg/kg/day) has not any anti-inflammatory and anti-nociceptive effect on RA. Based on the present results, we demonstrated that BVA might be a effective fraction in whole BV for long-term treatment of RA-induced pain and inflammation. However, it is clear necessary that further fraction study about BVA was required for elucidating an effective component of BVA.

Long-term cardiac composite risk following adjuvant treatment in breast cancer patients

  • Choi, Hong Bae;Yun, Sangchul;Cho, Sung Woo;Lee, Min Hyuk;Lee, Jihyoun;Park, Suyeon
    • Korean Journal of Clinical Oncology
    • /
    • v.14 no.2
    • /
    • pp.102-107
    • /
    • 2018
  • Purpose: Cardiotoxicity is a serious late complication of breast cancer treatment. Individual treatment risk of specific drugs has been investigated. However, studies on the evaluation of the composite risk of chemotherapeutic agents are limited. Methods: We retrospectively analyzed the medical records of breast cancer patients who received adjuvant treatment and had available serial echocardiography results. Patients were assigned to subgroups based on chemotherapy containing anthracyclines (A), anthracyclines and taxanes (A+T), and radiotherapy (RT). The development of cardiac disease and serial ejection fraction (EF) were reviewed. EF decline up to 10% from baseline was considered grade 1 cardiotoxicity and EF decline >20% or absolute value <50% was considered grade 2 cardiotoxicity. The most recent medical records and echocardiography results over 1 year of chemotherapy completion were also reviewed. Late cardiotoxicity was defined as a lack of recovery of EF decline or aggravated EF decline from baseline. Results: In total, 123 patients were evaluated. A small reduction in EF was observed after chemotherapy in both chemotherapy groups. There were no significant differences between groups A and A+T in EF decline following chemotherapy. We could not find any differences in composite risk between the chemotherapy groups and the RT group during follow-up. Late cardiotoxicity was seen in 15.45% of patients. During follow-up, three patients were diagnosed with dilated cardiomyopathy. Conclusion: There was no significant composite risk elevation following adjuvant treatment of breast cancer. However, late cardiotoxicity was considerable and further research in this direction is necessary.

A Review of Acupuncture on Hot Flashes during Adjuvant Endocrine Therapy in Breast Cancer Patients (유방암 환자의 호르몬 보조 요법 중 발생한 안면홍조에 대한 침 치료의 고찰)

  • Woo-Jin Jung;Da-Won Lee;Min-Jeong Kwon;Hyun-A Sim;Jong-Hyun Lee;Jae-Joong Jung
    • The Journal of Korean Obstetrics and Gynecology
    • /
    • v.37 no.3
    • /
    • pp.49-62
    • /
    • 2024
  • Objects: This study was conducted to examine the effect of acupuncture on hot flashes symptoms that occurred after adjuvant endocrine therapy in breast cancer patients. Methods: A total of 7 electronic databases, including Pubmed, Cochrane Central, Embase, and CNKI, were used to search for randomized controlled trials studies on acupuncture treatment for hot flashes that occurred after adjuvant endocrine therapy in breast cancer patients. Studies published from January 2014 to March 2024 were targeted, and Breast Cancer, Hot Flashes, Acupuncture, and Electroacupuncture were used as search keywords. The intervention method, treatment period and follow-up period, results, side effects, and acupuncture points were analyzed. Results: According to the inclusion criteria, 7 studies were finally selected. Acupuncture, electroacupuncture, acupuncture and enhanced self-care were combined as intervention methods of the treatment group, and the most common control group was the use of sham acupuncture. The selected study was evaluated by the symptoms of hot flashes, quality of life, depression, and quality of sleep. In terms of hot flashes, quality of life, and depression, a significant number of treatment groups showed improvement results than control group. The most commonly used acupuncture points in the study were 百會 (GV20), 關元 (CV4), 氣海 (CV6) each of which was used twice. Conclusions: According to this study, the improvement of symptoms was confirmed when acupuncture and electroacupuncture treatment were used for hot flashes that occurred during breast cancer adjuvant endocrine therapy.

Clinical Responses of Ultrasound on Adjuvant-Induced Arthritis in Rats (Adjuvant로 유발된 관절염의 흰 쥐에서 초음파의 임상반응)

  • Lee, Dong-Jin
    • Physical Therapy Korea
    • /
    • v.10 no.2
    • /
    • pp.45-59
    • /
    • 2003
  • The purpose of this study was to assess the effects of ultrasound on adjuvant-induced arthritis in rats. Adjuvant arthritis was induced in 26 female Sprauge-Dawley rats by the subcutaneous injection of a single dose of .1 mL of Complete Freund's Adjuvant (CFA) (1 mg of Mycobacterium Butyricum suspended in .1 $m{\ell}$ paraffin oil) into the right hind paw. After confirming inflammatory edema and arthritis in the paw 2 weeks later, the arthritic rats were divided into 3 groups, i.e., a control group, a pulsed ultrasound group (Group A), and a continuous ultrasound group (Group B) with 8 rats placed in each group. The rats in Group A were treated with pulsed ultrasound at 1 MHz frequency with .5 $W/cm^2$ intensity in 1 : 4 mode for 3 minutes. The rats in Group B were treated with continuous ultrasound at 1 MHz frequency with 2 $W/cm^2$ intensity in the continuous mode for 3 minutes. The ultrasound treatment was done in the left and right ankles for 2 weeks. Clinical, radiographic and histopathologic findings were then evaluated before and after treatment and yielded the following results. 1. No significant difference was present in body weight between the control group and the treated groups. 2. A statistically significant decrease in the edema of the paw was seen in the rats in Group A that was treated with pulsed ultrasound by 26~29 days after the treatment started (p<.05). 3. According to radiological examination, Group A showed the lowest score in arthritis scale which means it showed a tendency to suppress arthritic inflammation of the left and right hind paws. However, no statistically significant difference was present in the score between the control group, Group A and Group B. 4. According to histopathologic findings, the degree of infiltration by inflammatory cells and hypertrophy of the synovium were less in Group A compared with the control group and Group B. The results of the study show that rats that were treated with the pulsed ultrasound effectively suppressed adjuvant arthritis. However, more effort is needed to objectively prove the effectiveness of ultrasound by developing more sensitive testing methods that could quantitatively evaluate the treatment effects of acute rheumatoid arthritis and by trying out different ultrasound treatment methods.

  • PDF

The Effect of Angelica gigas NAKAI Pharmacopuncture at $ST_{36}$ and $BL_{23}$ on Freund's Adjuvant Arthritis in Rats (족삼리(足三里)($ST_{36}$).신수(腎兪)($BL_{23}$)에 대한 당귀약침이 Freund's Adjuvant로 유발된 백서(白鼠)의 관절염에 미치는 영향)

  • Ryu, Mi-Seon;Yun, Yeo-Choong;Kim, Jae-Hong
    • Journal of Acupuncture Research
    • /
    • v.27 no.5
    • /
    • pp.25-34
    • /
    • 2010
  • Objectives : The purpose of this study is to investigate that effect of Angelica gigas NAKAI pharmacopuncture(AGN-Ph) by concentration at $ST_{36}$(足三里) and $BL_{23}$(腎兪) in Freund's adjuvant rats. Methods : The experimental model of arthritis was induced by injection of Freund's adjuvant into Sprague Dawley(SD) rats. After arthritis was induced, AGN-Ph was injected by concentration at $ST_{36}$ and $BL_{23}$ of rats every other day for 6 times. Thereafter, edema rate, body weight, IFN-${\gamma}$, TNF-${\alpha}$, hematologic assay were measured. Results : The results were as follows, 1. After 3 times AGN-Ph treatment, the mean of edema rate was significantly decreased in AGN-Ph group 3 than control group. And after 6 times AGN-Ph treatment, the mean of edema rate was significantly decreased in AGN-Ph group 1, 2, 3 than control group. 2. The mean of body weight was significantly increased in AGN-Ph group 1, 3 than control group and saline group. 3. The mean of IFN-${\gamma}$ was significantly increased in AGN-Ph group 3 than control group. 4. The mean of TNF-${\alpha}$ was significantly increased in saline group than control group. But the mean of TNF-${\alpha}$ in AGN-Ph group 2, 3 showed no significance compared with control group's. 5. In hematologic assay, levels of WBC, RBC, Hemoglobin, Hematocrit showed no significance in all groups. Conclusions : These results are suggest that the Angelica gigas NAKAI pharmacopuncture(AGN-Ph) at $ST_{36}$ and $BL_{23}$ has a suppressing inflammation effect on Freund's adjuvant arthritis in rats.

Effects of Ethanol Extract of Potato (Solanum tuberlosum) on Freund's Complete Adjuvant-induced Model of Chronic Arthritis in Mice

  • Choi, Eun-Mi;Lee, Kyung-Hee;Koo, Sung-Ja
    • Food Science and Biotechnology
    • /
    • v.14 no.2
    • /
    • pp.228-232
    • /
    • 2005
  • The effect of a potato ethanol extract was investigated on Freund's complete adjuvant (FCA)-induced arthritis. The oral administration of the potato extract, at doses of 100 and 200 mg/kg once a day for 21 days, significantly reduced hindpaw swelling and the production of inflammatory cytokines (TNF-${\alpha}$, IL-$1{\beta}$ and IL-6). Treatment with the potato extract also decreased the plasma levels of creatinine, triglyceride and LDL-cholesterol, and the activities of AST and ALT compared with those of a control group. These results suggest that the potato extract might be beneficial in the treatment of chronic inflammatory disorders.